June 9, 2020
Astellas Pharma said on June 8 that its hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor Evrenzo (roxadustat) hit the primary endpoint in a multinational PIII study gauging the drug for the treatment of anemia in non-dialysis dependent patients with chronic kidney...read more